Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

PURPOSE: Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabolite of irinotecan. PATIENTS AND METHODS: We eval...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Bardia, Aditya, Mayer, Ingrid A., Diamond, Jennifer R., Moroose, Rebecca L., Isakoff, Steven J., Starodub, Alexander N., Shah, Nikita C., O’Shaughnessy, Joyce, Kalinsky, Kevin, Guarino, Michael, Abramson, Vandana, Juric, Dejan, Tolaney, Sara M., Berlin, Jordan, Messersmith, Wells A., Ocean, Allyson J., Wegener, William A., Maliakal, Pius, Sharkey, Robert M., Govindan, Serengulam V., Goldenberg, David M., Vahdat, Linda T.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2017
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559902/
https://ncbi.nlm.nih.gov/pubmed/28291390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.8297
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires